DBH-AS1: A Promising Drug Target and Biomarker for DSRNA Viruses

Target Name: DBH-AS1

NCBI ID: G138948

DBH-AS1

Other Name(s): DBH antisense RNA 1 | NCRNA00118

DBH-AS1: A Promising Drug Target and Biomarker for DSRNA Viruses

Doublestranded RNA (dsRNA) viruses, such as Hepatitis B virus (HBV), have a large double-stranded RNA genome that is expressed in the form of a positive sense RNA (ssRNA). The virus replicates by transmitting the double-stranded RNA genome into host cells, leading to the production of new viral particles. The use of antisense RNA drugs, such as DBH-AS1, can be an effective strategy to treat dsRNA viruses by inhibiting the viral replication. In this article, we will discuss DBH- AS1, a drug target and biomarker for dsRNA viruses, and its potential in the treatment of such viruses.

DBH-AS1: A Potential Drug Target

DBH-AS1 is a small interfering RNA (siRNA) designed to target the HBsAg gene of HBV. HBsAg is a viral envelope protein that is present in the majority of HBV-infected individuals and is used as a marker for the virus's replication. DBH-AS1 AS1 was synthesized using a novel technique called DNA-based synthesis and is composed of 20nt of single-stranded RNA and 19nt of a reverse sense complementary DNA (cDNA). DBH-AS1 is designed to hybridize with the HBsAg gene and prevent the virus from replicating.

DBH-AS1 has been shown to be effective in animal models of HBV infection. Studies have shown that DBH-AS1 can effectively reduce the level of HBsAg in both infected mice and human primary cells and can effectively block the virus's replication. also been shown to be safe and non-toxic when administered to humans.

DBH-AS1: A Potential Biomarker

DBH-AS1 has also been used as a potential biomarker for HBV infection. The level of DBH-AS1 in the blood can be used as an indicator of the virus's replication and can be used to monitor the effectiveness of DBH-AS1-based treatments. Studies have shown that the level of DBH-AS1 in the blood can be accurately measured and correlated with the level of HBsAg in the plasma. This makes DBH-AS1 an attractive potential biomarker for HBV infection.

DBH-AS1 has also been shown to be effective in treating other dsRNA viruses, such as rabies virus and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Studies have shown that DBH-AS1 can effectively reduce the level of viral particles in infected cells and can effectively block the virus's replication. This suggests that DBH-AS1 may be an effective treatment for a wide range of dsRNA viruses.

Conclusion

DBH-AS1 is a promising drug target and biomarker for dsRNA viruses, such as HBV. Studies have shown that DBH-AS1 can effectively reduce the level of HBsAg in both infected mice and human primary cells and can effectively block the virus's replication. DBH-AS1 AS1 has also been shown to be safe and non-toxic when administered to humans, making it an attractive potential treatment option for dsRNA viruses. Further research is needed to fully understand the potential of DBH-AS1 as a drug target and biomarker for dsRNA viruses. .

Protein Name: DBH Antisense RNA 1

The "DBH-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DBH-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets